<?xml version="1.0" encoding="UTF-8"?>
<Label drug="picato" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">      6 ADVERSE REACTIONS  

      



 The following serious adverse reactions are discussed in more detail in other sections of the labeling:



     



 *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]  
 *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]  
    
 

   EXCERPT:   The most common adverse reactions (&gt;=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache. (    6.1    )



   To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma Inc. at 1-877-494-4536 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    



 

  6.1 Clinical Trials Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.



 



 The data described below reflect exposure to Picato  (r)  gel in 499 subjects with actinic keratosis, including 274 subjects exposed to Picato  (r)  gel field treatment (skin area of 25 cm  2  in the face or scalp regions) at a concentration of 0.015% once daily for 3 consecutive days, and 225 subjects exposed to Picato  (r)  gel field treatment (skin area of 25 cm  2  in the trunk or extremities regions) at a concentration of 0.05% once daily for 2 consecutive days.



 



 Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4. A grade of 0 represented no reaction present in the treated area, and a grade of 4 indicated a marked and severe skin reaction that extended beyond the treated area.



 



   Table 1 Investigator Assessment of Maximal Local Skin Reactions in the Treatment Area during the 57 Days Post Treatment Period (face/scalp trials)  




  Face and Scalp  (n=545)  Picato(r) gel, 0.015% once daily for 3 days    
  Skin reactions             Any Gradea &gt; Baseline      Grade 4                    
                             Picato(r) gel  (n=274)     Vehicle  (n=271)           Picato(r) gel  (n=274)      Vehicle  (n=271)           
  Erythema                   258 (94%)                  69 (25%)                   66 (24%)                   0 (0%)                     
  Flaking/Scaling            233 (85%)                  67 (25%)                   25 (9%)                    0 (0%)                     
  Crusting                   220 (80%)                  46 (17%)                   16 (6%)                    0 (0%)                     
  Swelling                   217 (79%)                  11 (4%)                    14 (5%)                    0 (0%)                     
  Vesiculation/Pustulation    154 (56%)                  1 (0%)                     15 (5%)                    0 (0%)                     
  Erosion/Ulceration         87 (32%)                   3 (1%)                     1 (0%)                     0 (0%)                     
        a  Mild (grade 1), Moderate (grade 2-3) or Severe (grade 4).
 

 



   Table 2 Investigator Assessment of Maximal Local Skin Reactions in the Treatment Area during the 57 Days Post Treatment Period (trunk/extremities trials)  




  Trunk and Extremities  (n=457)  Picato(r) gel, 0.05% once daily for 2 days    
  Skin reactions             Any Gradea &gt; Baseline      Grade 4                    
                             Picato(r) gel  (n=225)     Vehicle  (n=232)           Picato(r) gel  (n=225)     Vehicle  (n=232)           
  Erythema                   207 (92%)                  43 (19%)                   34 (15%)                   0 (0%)                     
  Flaking/Scaling            203 (90%)                  44 (19%)                   18 (8%)                    0 (0%)                     
  Crusting                   167 (74%)                  23 (10%)                   8 (4%)                     0 (0%)                     
  Swelling                   143 (64%)                  13 (6%)                    7 (3%)                     0 (0%)                     
  Vesiculation/Pustulation    98 (44%)                   2 (1%)                     3 (1%)                     0 (0%)                     
  Erosion/Ulceration         58 (26%)                   6 (3%)                     2 (1%)                     0 (0%)                     
        a  Mild (grade 1), Moderate (grade 2-3) or Severe (grade 4).
 

 



 Local skin reactions typically occurred within 1 day of treatment initiation, peaked in intensity up to 1 week following completion of treatment, and resolved within 2 weeks for areas treated on the face and scalp, and within 4 weeks for areas treated on the trunk and extremities.



 



 Adverse reactions that occurred in &gt;=2% of subjects treated with Picato  (r)  gel and at a higher frequency than the vehicle are presented in Table 3 and Table 4.



 



   Table 3 Adverse reactions occurring in &gt;= 2% of subjects treated with Picato  (r)  gel and at higher frequency than vehicle (face/scalp trials)  




                             Face/Scalp                 
  Adverse Reactions          Picato(r) gel, 0.015%  (N=274)    Vehicle  (N=271)           
  
  Application Site Pain      42 (15%)                   1 (0%)                     
  Application Site Pruritus    22 (8%)                    3 (1%)                     
  Application Site Infection    7 (3%)                     0 (0%)                     
  Periorbital Edema          7 (3%)                     0 (0%)                     
  Headache                   6 (2%)                     3 (1%)                     
      
 

   Table 4 Adverse reactions occurring in &gt;= 2% of subjects treated with Picato  (r)  gel and at higher frequency than vehicle (trunk/extremities trials)  




                             Trunk/Extremities          
  Adverse Reactions          Picato(r) gel, 0.05%  (N=225)    Vehicle  (N=232)           
  Application Site Pruritus    18 (8%)                    0 (0%)                     
  Application Site Irritation    8 (4%)                     1 (0%)                     
  Nasopharyngitis            4 (2%)                     2 (1%)                     
  Application Site Pain      5 (2%)                     0 (0%)                     
      
 

 Less common adverse reactions in subjects treated with Picato  (r)  included: eyelid edema, eye pain, conjunctivitis.



 



 A total of 108 subjects treated with Picato  (r)  gel on the face/scalp and 38 subjects treated on the trunk/extremities were followed for 12 months. Results from these studies did not change the safety profile of Picato  (r)  gel.



   6.2 Postmarketing Experience

  The following adverse reactions have been identified during post approval use of Picato  (r)  (ingenol mebutate) gel, 0.015% and 0.05%: hypersensitivity, allergic contact dermatitis, herpes zoster, chemical conjunctivitis, and corneal burn.



 Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</Section>
    <Section name="warnings and precautions" id="S2">     5 WARNINGS AND PRECAUTIONS  



  EXCERPT:   Avoid treatment in the periocular area. Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure. Avoid accidental transfer of the drug into the eyes and to the periocular area. If accidental exposure occurs, flush eyes with water and seek medical care. (  5.1  )



 



 Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration). Administration of Picato  (r)  gel is not recommended until skin is healed from any previous drug or surgical treatment. (  5.3  )



 



   5.1 Ophthalmic Adverse Reactions



  Avoid treatment in the periocular area. Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure [see Adverse Reactions (  6  )]   .  



 



 To avoid transfer of the drug into the eyes and to the periocular area during and after application, patients should wash hands well after applying Picato  (r)   gel. If accidental exposure occurs, the area should be flushed with water and the patient should seek medical care as soon as possible.  



    5.2 Hypersensitivity Reactions



  Hypersensitivity reactions, including anaphylaxis and allergic contact dermatitis, have been reported post-marketing [see Adverse Reactions (  6.2  )]  . If anaphylactic or other clinically significant hypersensitivity reactions occur, discontinue Picato  (r)  immediately and institute appropriate medical therapy.



    5.3 Local Skin Reactions



  Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  . Administration of Picato  (r)  gel is not recommended until the skin is healed from any previous drug or surgical treatment.
</Section>
  </Text>
  <Mentions>
    <Mention id="M1" section="S1" type="AdverseReaction" start="160" len="27" str="Ophthalmic Adverse Reaction" />
    <Mention id="M2" section="S1" type="AdverseReaction" start="235" len="26" str="Hypersensitivity Reactions" />
    <Mention id="M3" section="S1" type="AdverseReaction" start="373" len="20" str="local skin reactions" />
    <Mention id="M4" section="S1" type="AdverseReaction" start="395" len="21" str="application site pain" />
    <Mention id="M5" section="S1" type="AdverseReaction" start="418" len="25" str="application site pruritus" />
    <Mention id="M6" section="S1" type="AdverseReaction" start="445" len="27" str="application site irritation" />
    <Mention id="M7" section="S1" type="AdverseReaction" start="474" len="26" str="application site infection" />
    <Mention id="M8" section="S1" type="AdverseReaction" start="502" len="17" str="periorbital edema" />
    <Mention id="M9" section="S1" type="AdverseReaction" start="521" len="15" str="nasopharyngitis" />
    <Mention id="M10" section="S1" type="AdverseReaction" start="541" len="8" str="headache" />
    <Mention id="M11" section="S1" type="AdverseReaction" start="1512" len="20" str="Local skin reactions" />
    <Mention id="M12" section="S1" type="AdverseReaction" start="1512,1544" len="10,8" str="Local skin erythema" />
    <Mention id="M13" section="S1" type="AdverseReaction" start="1512,1554" len="10,7" str="Local skin flaking" />
    <Mention id="M14" section="S1" type="AdverseReaction" start="1512,1562" len="10,7" str="Local skin scaling" />
    <Mention id="M15" section="S1" type="AdverseReaction" start="1512,1571" len="10,8" str="Local skin crusting" />
    <Mention id="M16" section="S1" type="AdverseReaction" start="1512,1581" len="10,8" str="Local skin swelling" />
    <Mention id="M17" section="S1" type="AdverseReaction" start="1512,1591" len="10,12" str="Local skin vesiculation" />
    <Mention id="M18" section="S1" type="AdverseReaction" start="1512,1604" len="10,11" str="Local skin pustulation" />
    <Mention id="M19" section="S1" type="AdverseReaction" start="1512,1621" len="10,7" str="Local skin erosion" />
    <Mention id="M20" section="S1" type="AdverseReaction" start="1512,1629" len="10,10" str="Local skin ulceration" />
    <Mention id="M21" section="S1" type="AdverseReaction" start="1962" len="20" str="Local Skin Reactions" />
    <Mention id="M22" section="S1" type="AdverseReaction" start="2149,2372" len="4,8" str="Skin Erythema" />
    <Mention id="M23" section="S1" type="AdverseReaction" start="2149,2510" len="4,7" str="Skin Flaking" />
    <Mention id="M24" section="S1" type="AdverseReaction" start="2149,2518" len="4,7" str="Skin Scaling" />
    <Mention id="M25" section="S1" type="AdverseReaction" start="2149,2648" len="4,8" str="Skin Crusting" />
    <Mention id="M26" section="S1" type="AdverseReaction" start="2149,2786" len="4,8" str="Skin Swelling" />
    <Mention id="M27" section="S1" type="AdverseReaction" start="2149,2924" len="4,12" str="Skin Vesiculation" />
    <Mention id="M28" section="S1" type="AdverseReaction" start="2149,2937" len="4,11" str="Skin Pustulation" />
    <Mention id="M29" section="S1" type="AdverseReaction" start="2149,3063" len="4,7" str="Skin Erosion" />
    <Mention id="M30" section="S1" type="AdverseReaction" start="2149,3071" len="4,10" str="Skin Ulceration" />
    <Mention id="M31" section="S1" type="AdverseReaction" start="3322" len="20" str="Local Skin Reactions" />
    <Mention id="M32" section="S1" type="AdverseReaction" start="3522,3744" len="4,8" str="Skin Erythema" />
    <Mention id="M33" section="S1" type="AdverseReaction" start="3522,3882" len="4,7" str="Skin Flaking" />
    <Mention id="M34" section="S1" type="AdverseReaction" start="3522,3890" len="4,7" str="Skin Scaling" />
    <Mention id="M35" section="S1" type="AdverseReaction" start="3522,4020" len="4,8" str="Skin Crusting" />
    <Mention id="M36" section="S1" type="AdverseReaction" start="3522,4158" len="4,8" str="Skin Swelling" />
    <Mention id="M37" section="S1" type="AdverseReaction" start="3522,4296" len="4,12" str="Skin Vesiculation" />
    <Mention id="M38" section="S1" type="AdverseReaction" start="3522,4309" len="4,11" str="Skin Pustulation" />
    <Mention id="M39" section="S1" type="AdverseReaction" start="3522,4435" len="4,7" str="Skin Erosion" />
    <Mention id="M40" section="S1" type="AdverseReaction" start="3522,4443" len="4,10" str="Skin Ulceration" />
    <Mention id="M41" section="S1" type="AdverseReaction" start="4649" len="20" str="Local skin reactions" />
    <Mention id="M42" section="S1" type="AdverseReaction" start="5417" len="21" str="Application Site Pain" />
    <Mention id="M43" section="S1" type="AdverseReaction" start="5501" len="25" str="Application Site Pruritus" />
    <Mention id="M44" section="S1" type="AdverseReaction" start="5587" len="26" str="Application Site Infection" />
    <Mention id="M45" section="S1" type="AdverseReaction" start="5674" len="17" str="Periorbital Edema" />
    <Mention id="M46" section="S1" type="AdverseReaction" start="5758" len="8" str="Headache" />
    <Mention id="M47" section="S1" type="AdverseReaction" start="6159" len="25" str="Application Site Pruritus" />
    <Mention id="M48" section="S1" type="AdverseReaction" start="6245" len="27" str="Application Site Irritation" />
    <Mention id="M49" section="S1" type="AdverseReaction" start="6333" len="15" str="Nasopharyngitis" />
    <Mention id="M50" section="S1" type="AdverseReaction" start="6417" len="21" str="Application Site Pain" />
    <Mention id="M51" section="S1" type="AdverseReaction" start="6588" len="12" str="eyelid edema" />
    <Mention id="M52" section="S1" type="AdverseReaction" start="6602" len="8" str="eye pain" />
    <Mention id="M53" section="S1" type="AdverseReaction" start="6612" len="14" str="conjunctivitis" />
    <Mention id="M54" section="S1" type="AdverseReaction" start="7043" len="16" str="hypersensitivity" />
    <Mention id="M55" section="S1" type="AdverseReaction" start="7061" len="27" str="allergic contact dermatitis" />
    <Mention id="M56" section="S1" type="AdverseReaction" start="7090" len="13" str="herpes zoster" />
    <Mention id="M57" section="S1" type="AdverseReaction" start="7105" len="23" str="chemical conjunctivitis" />
    <Mention id="M58" section="S1" type="AdverseReaction" start="7134" len="12" str="corneal burn" />
    <Mention id="M59" section="S2" type="AdverseReaction" start="90" len="13" str="Eye disorders" />
    <Mention id="M60" section="S2" type="Severity" start="115" len="6" str="severe" />
    <Mention id="M61" section="S2" type="AdverseReaction" start="122" len="8" str="eye pain" />
    <Mention id="M62" section="S2" type="AdverseReaction" start="132" len="23" str="chemical conjunctivitis" />
    <Mention id="M63" section="S2" type="AdverseReaction" start="157" len="12" str="corneal burn" />
    <Mention id="M64" section="S2" type="AdverseReaction" start="171" len="12" str="eyelid edema" />
    <Mention id="M65" section="S2" type="AdverseReaction" start="185" len="13" str="eyelid ptosis" />
    <Mention id="M66" section="S2" type="AdverseReaction" start="200" len="17" str="periorbital edema" />
    <Mention id="M67" section="S2" type="Factor" start="218" len="3" str="can" />
    <Mention id="M68" section="S2" type="AdverseReaction" start="419" len="20" str="Local skin reactions" />
    <Mention id="M69" section="S2" type="AdverseReaction" start="419,484" len="10,12" str="Local skin vesiculation" />
    <Mention id="M70" section="S2" type="AdverseReaction" start="419,497" len="10,11" str="Local skin pustulation" />
    <Mention id="M71" section="S2" type="AdverseReaction" start="419,510" len="10,7" str="Local skin erosion" />
    <Mention id="M72" section="S2" type="AdverseReaction" start="419,518" len="10,10" str="Local skin ulceration" />
    <Mention id="M73" section="S2" type="Factor" start="440" len="3" str="can" />
    <Mention id="M74" section="S2" type="Severity" start="460" len="6" str="severe" />
    <Mention id="M75" section="S2" type="AdverseReaction" start="751" len="13" str="Eye disorders" />
    <Mention id="M76" section="S2" type="Severity" start="776" len="6" str="severe" />
    <Mention id="M77" section="S2" type="AdverseReaction" start="783" len="8" str="eye pain" />
    <Mention id="M78" section="S2" type="AdverseReaction" start="793" len="23" str="chemical conjunctivitis" />
    <Mention id="M79" section="S2" type="AdverseReaction" start="818" len="12" str="corneal burn" />
    <Mention id="M80" section="S2" type="AdverseReaction" start="832" len="12" str="eyelid edema" />
    <Mention id="M81" section="S2" type="AdverseReaction" start="846" len="13" str="eyelid ptosis" />
    <Mention id="M82" section="S2" type="AdverseReaction" start="861" len="17" str="periorbital edema" />
    <Mention id="M83" section="S2" type="Factor" start="879" len="3" str="can" />
    <Mention id="M84" section="S2" type="AdverseReaction" start="1294" len="26" str="Hypersensitivity reactions" />
    <Mention id="M85" section="S2" type="AdverseReaction" start="1332" len="11" str="anaphylaxis" />
    <Mention id="M86" section="S2" type="AdverseReaction" start="1348" len="27" str="allergic contact dermatitis" />
    <Mention id="M87" section="S2" type="Severity" start="1647" len="6" str="Severe" />
    <Mention id="M88" section="S2" type="AdverseReaction" start="1654" len="34" str="skin reactions in the treated area" />
    <Mention id="M89" section="S2" type="AdverseReaction" start="1654,1700" len="34,8" str="skin reactions in the treated area erythema" />
    <Mention id="M90" section="S2" type="AdverseReaction" start="1654,1710" len="34,8" str="skin reactions in the treated area crusting" />
    <Mention id="M91" section="S2" type="AdverseReaction" start="1654,1720" len="34,8" str="skin reactions in the treated area swelling" />
    <Mention id="M92" section="S2" type="AdverseReaction" start="1654,1730" len="34,12" str="skin reactions in the treated area vesiculation" />
    <Mention id="M93" section="S2" type="AdverseReaction" start="1654,1743" len="34,11" str="skin reactions in the treated area postulation" />
    <Mention id="M94" section="S2" type="AdverseReaction" start="1654,1760" len="34,7" str="skin reactions in the treated area erosion" />
    <Mention id="M95" section="S2" type="AdverseReaction" start="1654,1768" len="34,10" str="skin reactions in the treated area ulceration" />
    <Mention id="M96" section="S2" type="Factor" start="1780" len="3" str="can" />
  </Mentions>
  <Relations>
    <Relation id="RL1" type="Hypothetical" arg1="M59" arg2="M67" />
    <Relation id="RL2" type="Hypothetical" arg1="M61" arg2="M67" />
    <Relation id="RL3" type="Effect" arg1="M61" arg2="M60" />
    <Relation id="RL4" type="Hypothetical" arg1="M62" arg2="M67" />
    <Relation id="RL5" type="Hypothetical" arg1="M63" arg2="M67" />
    <Relation id="RL6" type="Hypothetical" arg1="M64" arg2="M67" />
    <Relation id="RL7" type="Hypothetical" arg1="M65" arg2="M67" />
    <Relation id="RL8" type="Hypothetical" arg1="M66" arg2="M67" />
    <Relation id="RL9" type="Hypothetical" arg1="M68" arg2="M73" />
    <Relation id="RL10" type="Effect" arg1="M69" arg2="M74" />
    <Relation id="RL11" type="Hypothetical" arg1="M69" arg2="M73" />
    <Relation id="RL12" type="Effect" arg1="M70" arg2="M74" />
    <Relation id="RL13" type="Hypothetical" arg1="M70" arg2="M73" />
    <Relation id="RL14" type="Effect" arg1="M71" arg2="M74" />
    <Relation id="RL15" type="Hypothetical" arg1="M71" arg2="M73" />
    <Relation id="RL16" type="Effect" arg1="M72" arg2="M74" />
    <Relation id="RL17" type="Hypothetical" arg1="M72" arg2="M73" />
    <Relation id="RL18" type="Hypothetical" arg1="M75" arg2="M83" />
    <Relation id="RL19" type="Effect" arg1="M77" arg2="M76" />
    <Relation id="RL20" type="Hypothetical" arg1="M77" arg2="M83" />
    <Relation id="RL21" type="Hypothetical" arg1="M78" arg2="M83" />
    <Relation id="RL22" type="Hypothetical" arg1="M79" arg2="M83" />
    <Relation id="RL23" type="Hypothetical" arg1="M80" arg2="M83" />
    <Relation id="RL24" type="Hypothetical" arg1="M81" arg2="M83" />
    <Relation id="RL25" type="Hypothetical" arg1="M82" arg2="M83" />
    <Relation id="RL26" type="Effect" arg1="M88" arg2="M87" />
    <Relation id="RL27" type="Hypothetical" arg1="M88" arg2="M96" />
    <Relation id="RL28" type="Hypothetical" arg1="M89" arg2="M96" />
    <Relation id="RL29" type="Hypothetical" arg1="M90" arg2="M96" />
    <Relation id="RL30" type="Hypothetical" arg1="M91" arg2="M96" />
    <Relation id="RL31" type="Hypothetical" arg1="M92" arg2="M96" />
    <Relation id="RL32" type="Hypothetical" arg1="M93" arg2="M96" />
    <Relation id="RL33" type="Hypothetical" arg1="M94" arg2="M96" />
    <Relation id="RL34" type="Hypothetical" arg1="M95" arg2="M96" />
  </Relations>
  <Reactions>
    <Reaction id="AR1" str="ophthalmic adverse reaction">
      <Normalization id="AR1.N1" meddra_pt="Eye symptom" meddra_pt_id="10075536" />
    </Reaction>
    <Reaction id="AR2" str="hypersensitivity reactions">
      <Normalization id="AR2.N1" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" meddra_llt="Hypersensitivity reaction" meddra_llt_id="10020756" />
    </Reaction>
    <Reaction id="AR3" str="local skin reactions">
      <Normalization id="AR3.N1" meddra_pt="Skin reaction" meddra_pt_id="10040914" meddra_llt="Localised skin reaction" meddra_llt_id="10024777" />
    </Reaction>
    <Reaction id="AR4" str="application site pain">
      <Normalization id="AR4.N1" meddra_pt="Application site pain" meddra_pt_id="10003051" />
    </Reaction>
    <Reaction id="AR5" str="application site pruritus">
      <Normalization id="AR5.N1" meddra_pt="Application site pruritus" meddra_pt_id="10003053" />
    </Reaction>
    <Reaction id="AR6" str="application site irritation">
      <Normalization id="AR6.N1" meddra_pt="Application site irritation" meddra_pt_id="10003046" />
    </Reaction>
    <Reaction id="AR7" str="application site infection">
      <Normalization id="AR7.N1" meddra_pt="Application site infection" meddra_pt_id="10049041" />
    </Reaction>
    <Reaction id="AR8" str="periorbital edema">
      <Normalization id="AR8.N1" meddra_pt="Periorbital oedema" meddra_pt_id="10034545" meddra_llt="Periorbital edema" meddra_llt_id="10054541" />
    </Reaction>
    <Reaction id="AR9" str="nasopharyngitis">
      <Normalization id="AR9.N1" meddra_pt="Nasopharyngitis" meddra_pt_id="10028810" />
    </Reaction>
    <Reaction id="AR10" str="headache">
      <Normalization id="AR10.N1" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Reaction>
    <Reaction id="AR11" str="local skin erythema">
      <Normalization id="AR11.N1" meddra_pt="Erythema" meddra_pt_id="10015150" meddra_llt="Skin erythema" meddra_llt_id="10040842" />
    </Reaction>
    <Reaction id="AR12" str="local skin flaking">
      <Normalization id="AR12.N1" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" meddra_llt="Flaking skin" meddra_llt_id="10016749" />
    </Reaction>
    <Reaction id="AR13" str="local skin scaling">
      <Normalization id="AR13.N1" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" meddra_llt="Flaking skin" meddra_llt_id="10016749" />
    </Reaction>
    <Reaction id="AR14" str="local skin crusting">
      <Normalization id="AR14.N1" meddra_pt="Scab" meddra_pt_id="10039509" meddra_llt="Crust" meddra_llt_id="10011468" />
      <Normalization id="AR14.N2" meddra_pt="Skin reaction" meddra_pt_id="10040914" meddra_llt="Localised skin reaction" meddra_llt_id="10024777" />
    </Reaction>
    <Reaction id="AR15" str="local skin swelling">
      <Normalization id="AR15.N1" meddra_pt="Skin swelling" meddra_pt_id="10053262" />
    </Reaction>
    <Reaction id="AR16" str="local skin vesiculation">
      <Normalization id="AR16.N1" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
      <Normalization id="AR16.N2" meddra_pt="Drug eruption" meddra_pt_id="10013687" meddra_llt="Drug eruption vesicular" meddra_llt_id="10013694" />
    </Reaction>
    <Reaction id="AR17" str="local skin pustulation">
      <Normalization id="AR17.N1" meddra_pt="Rash pustular" meddra_pt_id="10037888" meddra_llt="Pustule" meddra_llt_id="10037578" />
      <Normalization id="AR17.N2" meddra_pt="Skin reaction" meddra_pt_id="10040914" meddra_llt="Localised skin reaction" meddra_llt_id="10024777" />
    </Reaction>
    <Reaction id="AR18" str="local skin erosion">
      <Normalization id="AR18.N1" meddra_pt="Skin erosion" meddra_pt_id="10040840" />
    </Reaction>
    <Reaction id="AR19" str="local skin ulceration">
      <Normalization id="AR19.N1" meddra_pt="Skin ulcer" meddra_pt_id="10040943" />
    </Reaction>
    <Reaction id="AR20" str="skin erythema">
      <Normalization id="AR20.N1" meddra_pt="Erythema" meddra_pt_id="10015150" meddra_llt="Skin erythema" meddra_llt_id="10040842" />
    </Reaction>
    <Reaction id="AR21" str="skin flaking">
      <Normalization id="AR21.N1" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" meddra_llt="Flaking skin" meddra_llt_id="10016749" />
    </Reaction>
    <Reaction id="AR22" str="skin scaling">
      <Normalization id="AR22.N1" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" meddra_llt="Skin peeling" meddra_llt_id="10040908" />
    </Reaction>
    <Reaction id="AR23" str="skin crusting">
      <Normalization id="AR23.N1" meddra_pt="Scab" meddra_pt_id="10039509" meddra_llt="Crust" meddra_llt_id="10011468" />
    </Reaction>
    <Reaction id="AR24" str="skin swelling">
      <Normalization id="AR24.N1" meddra_pt="Skin swelling" meddra_pt_id="10053262" />
    </Reaction>
    <Reaction id="AR25" str="skin vesiculation">
      <Normalization id="AR25.N1" meddra_pt="Blister" meddra_pt_id="10005191" meddra_llt="Vesicles" meddra_llt_id="10047368" />
    </Reaction>
    <Reaction id="AR26" str="skin pustulation">
      <Normalization id="AR26.N1" meddra_pt="Rash pustular" meddra_pt_id="10037888" meddra_llt="Pustule" meddra_llt_id="10037578" />
    </Reaction>
    <Reaction id="AR27" str="skin erosion">
      <Normalization id="AR27.N1" meddra_pt="Skin erosion" meddra_pt_id="10040840" />
    </Reaction>
    <Reaction id="AR28" str="skin ulceration">
      <Normalization id="AR28.N1" meddra_pt="Skin ulcer" meddra_pt_id="10040943" meddra_llt="Skin ulceration" meddra_llt_id="10040947" />
    </Reaction>
    <Reaction id="AR29" str="eyelid edema">
      <Normalization id="AR29.N1" meddra_pt="Eyelid oedema" meddra_pt_id="10015993" meddra_llt="Eyelid edema" meddra_llt_id="10015985" />
    </Reaction>
    <Reaction id="AR30" str="eye pain">
      <Normalization id="AR30.N1" meddra_pt="Eye pain" meddra_pt_id="10015958" />
    </Reaction>
    <Reaction id="AR31" str="conjunctivitis">
      <Normalization id="AR31.N1" meddra_pt="Conjunctivitis" meddra_pt_id="10010741" />
    </Reaction>
    <Reaction id="AR32" str="hypersensitivity">
      <Normalization id="AR32.N1" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Reaction>
    <Reaction id="AR33" str="allergic contact dermatitis">
      <Normalization id="AR33.N1" meddra_pt="Dermatitis contact" meddra_pt_id="10012442" meddra_llt="Allergic contact dermatitis" meddra_llt_id="10056265" />
    </Reaction>
    <Reaction id="AR34" str="herpes zoster">
      <Normalization id="AR34.N1" meddra_pt="Herpes zoster" meddra_pt_id="10019974" />
    </Reaction>
    <Reaction id="AR35" str="chemical conjunctivitis">
      <Normalization id="AR35.N1" meddra_pt="Chemical eye injury" meddra_pt_id="10055116" meddra_llt="Chemical conjunctivitis" meddra_llt_id="10055119" />
    </Reaction>
    <Reaction id="AR36" str="corneal burn">
      <Normalization id="AR36.N1" meddra_pt="Eye burns" meddra_pt_id="10015911" meddra_llt="Corneal burn" meddra_llt_id="10068161" />
    </Reaction>
    <Reaction id="AR37" str="eye disorders">
      <Normalization id="AR37.N1" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
    </Reaction>
    <Reaction id="AR38" str="eyelid ptosis">
      <Normalization id="AR38.N1" meddra_pt="Eyelid ptosis" meddra_pt_id="10015995" />
    </Reaction>
    <Reaction id="AR39" str="anaphylaxis">
      <Normalization id="AR39.N1" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" meddra_llt="Anaphylaxis" meddra_llt_id="10002218" />
    </Reaction>
    <Reaction id="AR40" str="skin reactions in the treated area">
      <Normalization id="AR40.N1" meddra_pt="Skin reaction" meddra_pt_id="10040914" meddra_llt="Localised skin reaction" meddra_llt_id="10024777" />
    </Reaction>
    <Reaction id="AR41" str="skin reactions in the treated area erythema">
      <Normalization id="AR41.N1" meddra_pt="Application site erythema" meddra_pt_id="10003041" />
    </Reaction>
    <Reaction id="AR42" str="skin reactions in the treated area crusting">
      <Normalization id="AR42.N1" meddra_pt="Application site scab" meddra_pt_id="10066209" />
    </Reaction>
    <Reaction id="AR43" str="skin reactions in the treated area swelling">
      <Normalization id="AR43.N1" meddra_pt="Application site swelling" meddra_pt_id="10053424" />
    </Reaction>
    <Reaction id="AR44" str="skin reactions in the treated area vesiculation">
      <Normalization id="AR44.N1" meddra_pt="Application site vesicles" meddra_pt_id="10048941" />
    </Reaction>
    <Reaction id="AR45" str="skin reactions in the treated area postulation">
      <Normalization id="AR45.N1" meddra_pt="Application site pustules" meddra_pt_id="10049044" />
    </Reaction>
    <Reaction id="AR46" str="skin reactions in the treated area erosion">
      <Normalization id="AR46.N1" meddra_pt="Application site erosion" meddra_pt_id="10065577" />
    </Reaction>
    <Reaction id="AR47" str="skin reactions in the treated area ulceration">
      <Normalization id="AR47.N1" meddra_pt="Application site ulcer" meddra_pt_id="10003059" />
    </Reaction>
  </Reactions>
</Label>
